3 Canadian Growth Stars Under $30

Investing in growth stocks and building a robust investment portfolio doesn’t require substantial funds. You can begin with as little as $30 and gradually move towards your financial objectives. The key is to buy and hold TSX stocks with solid fundamentals and promising long-term growth potential. You can accumulate significant wealth over time by consistently buying

3 Canadian Growth Stars Under $30 Read More »

CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event

CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event Live video webcast onWednesday, January 18that10:00 AM ET HOUSTON,January 5, 2023/PRNewswire/ —CNS Pharmaceuticals, Inc.(NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today

CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event Read More »

Oracle shares rise 9% after Trump unveils $500 billion AI plan By Reuters

LONDON (Reuters) – Oracle (NYSE:) shares jumped nearly 9% in Frankfurt on Wednesday, after U.S. President Donald Trump said the company would make a large investment in artificial intelligence infrastructure, together with OpenAI and SoftBank (TYO:). The joint venture, called Stargate, plans to invest $500 billion, Trump said at the White House the previous day.

Oracle shares rise 9% after Trump unveils $500 billion AI plan By Reuters Read More »

Pantheon Resources eyes resource boost at Megrez-1 well By Investing.com

LONDON – Pantheon Resources plc (AIM:PANR, OTCQX: PTHRF), an oil and gas exploration company, has announced preliminary findings from the Megrez-1 well on Alaska’s North Slope that suggest a significant increase in hydrocarbon resources. The company, which is developing the Kodiak and Ahpun oil fields, detailed the results during the Sequire Investor Summit today. The

Pantheon Resources eyes resource boost at Megrez-1 well By Investing.com Read More »

Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023

– Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib – – 2/3 Partial Responses in Lymphoma and 11/15 Stable Disease in Advanced Solid Tumors– – Expecting Key Data Readouts for Oral Fadraciclib in 2023– – Expecting Preliminary Safety and Efficacy Update for Oral Plogosertib (formerly CYC140) in

Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023 Read More »